Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

Rhea-AI Summary

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF), a biopharmaceutical company focused on infectious diseases and medical countermeasures, held its annual and special meeting of shareholders on September 17, 2024. All tabled resolutions were approved, including the election of six directors: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni, and Prakash Gowd. The shareholders also approved the re-appointment of PricewaterhouseCoopers, LLP as the independent auditor, and passed special resolutions for the Company's continuation from the Canada Business Corporations Act to the Ontario Business Corporations Act (OBCA). Additionally, shareholders authorized the board to set the number of directors within the limits set in the Company's articles, in accordance with the OBCA.

Positive

• All proposed resolutions were approved by shareholders
• Six directors were elected with high approval percentages, ranging from 94.54% to 99.45%
• Special resolution passed for the Company's continuation to Ontario Business Corporations Act

Negative

• None.

HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its annual and special meeting of shareholders held earlier today.

Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including the election of the following directors for the ensuing year: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni and Prakash Gowd.

Voting results for each director are summarized below:

Name of Nominee	Percentage of Votes For	Percentage of Votes Against
Don Cilla	27,929,188 (94.54%)	1,612,685 (5.46%)
Brian Bloom	28,409,188 (96.17%)	1,132,685 (3.83%)
Theresa Matkovits	29,377,973 (99.45%)	163,900 (0.55%)
Juergen Froehlich	29,377,973 (99.45%)	163,900 (0.55%)
Armand Balboni	28,409,188 (96.17%)	1,132,685 (3.83%)
Prakash Gowd	29,377,973 (99.45%)	163,900 (0.55%)

All other matters considered at the Meeting were approved by shareholders, including the re-appointment of PricewaterhouseCoopers, LLP, Chartered Accountants, as the independent auditor of the Company for the ensuing year and authorized the directors of the Company to fix their remuneration, a special resolution approving the Company’s continuation (the “Continuance") from a corporation governed under the Canada Business Corporations Act to a corporation governed under the Business Corporations Act (Ontario) (“OBCA”) and special resolution to authorize the board of directors of the Company, following the Continuance, to set the number of directors from time to time within the minimum and maximum number of directors set forth in the articles of the Company, in accordance with Section 125(3) of the OBCA.

The Company has filed a report of the voting results on all resolutions voted on the Meeting on the Company’s SEDAR+ profile at www.sedarplus.ca.

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

Media Contact:
Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: JMcNeil@AppiliTherapeutics.com

Investor Relations Contact:
Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: Info@AppiliTherapeutics.com

FAQ

What were the main outcomes of Appili Therapeutics' (APLIF) annual and special meeting on September 17, 2024?

The main outcomes were the approval of all tabled resolutions, including the election of six directors, re-appointment of PricewaterhouseCoopers as auditor, and special resolutions for the Company's continuation to the Ontario Business Corporations Act.

Who were the directors elected to Appili Therapeutics' (APLIF) board in the September 2024 meeting?

The elected directors were Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni, and Prakash Gowd.

What special resolutions did Appili Therapeutics (APLIF) shareholders approve in the September 2024 meeting?

Shareholders approved the Company's continuation from the Canada Business Corporations Act to the Ontario Business Corporations Act, and authorized the board to set the number of directors within the limits set in the Company's articles.

What was the voting result for Appili Therapeutics' (APLIF) director elections in September 2024?

The voting results showed high approval rates for all directors, with percentages ranging from 94.54% to 99.45% in favor of each nominee.